Asset Details
Do you wish to reserve the book?
Peripheral Blood Mononuclear Cells in Sepsis: Immune Trajectories, Monocyte Dysfunction, and Translational Biomarkers
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Peripheral Blood Mononuclear Cells in Sepsis: Immune Trajectories, Monocyte Dysfunction, and Translational Biomarkers
Do you wish to request the book?
Peripheral Blood Mononuclear Cells in Sepsis: Immune Trajectories, Monocyte Dysfunction, and Translational Biomarkers
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Peripheral Blood Mononuclear Cells in Sepsis: Immune Trajectories, Monocyte Dysfunction, and Translational Biomarkers
2026
Overview
Sepsis is characterized by a dynamic and heterogeneous immune response in which hyperinflammation and immunosuppression often coexist and change over time. Peripheral blood mononuclear cells (PBMCs), including monocytes and lymphocyte subsets, provide an accessible window into this evolving immune trajectory and can be repeatedly assessed during disease progression. In this narrative review, we synthesize recent evidence from single-cell and spatial omics, mechanistic studies, and PBMC-based biomarker research, with a focus on three connected themes: time-dependent PBMC remodeling, monocyte/macrophage dysfunction, and translational immune biomarkers. Current evidence indicates that PBMC remodeling in sepsis is marked by monocyte state transitions, HLA-DR downregulation, lymphocyte apoptosis and exhaustion, regulated cell death, and immunometabolic reprogramming. These changes help explain why some patients recover after the acute inflammatory phase, whereas others progress toward persistent immunoparalysis, secondary infection, prolonged critical illness, or poor outcomes. PBMC-derived biomarkers, including transcriptomic signatures, monocyte phenotypes, lymphocyte exhaustion markers, metabolic indicators, and functional immune assays, may improve immune phenotyping and risk stratification. However, clinical translation remains limited by cohort heterogeneity, age-related differences, timing-dependent immune states, assay standardization, and insufficient prospective validation. Future studies should prioritize longitudinal, age-stratified, and biomarker-guided designs to determine whether PBMC-based immune monitoring can support individualized immunomodulatory strategies in sepsis.
Publisher
Dove Press,Dove Medical Press
